Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T Oliver

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
Statistics in Medicine|November 15, 1994
On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma SubgroupP M Fayers, P A Cook, D Machin, et al.
Cytogenetics and Cell Genetics|November 10, 2001
The characterisation of the lymphoma cell line U937, using comparative genomic hybridisation and multi-plex FISHJ C Strefford, N J Foot, T Chaplin, et al.
Lancet (London, England)|August 17, 1985
Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervixA A Epenetos, D Snook, G Hooker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapyJ Shamash, R T Oliver, J Ong, et al.
British Medical Journal (Clinical Research Ed.)|April 23, 1983
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancerJ H Waxman, J A Wass, W F Hendry, et al.
Oncology Reports|December 22, 1999
Concordance between tumour cell activation by epidermal growth factor and alteration of cell sensitivity to cisplatin and lymphokine-activated killer cell activityA M Nouri, S T Zubairi, M V Russell, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
The first clinical use of depot buserelin for advanced prostatic carcinomaJ H Waxman, J Sandow, A Man, et al.
Acta Oncologica (Stockholm, Sweden)|January 6, 2001
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?J Shamash, C A O'Doherty, R T Oliver, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Secondary tumours following etoposide containing therapy for germ cell cancerC Boshoff, R H Begent, R T Oliver, et al.
BJU International|November 9, 2000
Computed tomography 21 days after chemotherapy, three-dimensional estimates of metastatic volume and the need for surgery in patients with germ cell cancerH S Bozcuk, R Ravi, B Turner, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
Statistics in Medicine|November 15, 1994
On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma SubgroupP M Fayers, P A Cook, D Machin, et al.
Cytogenetics and Cell Genetics|November 10, 2001
The characterisation of the lymphoma cell line U937, using comparative genomic hybridisation and multi-plex FISHJ C Strefford, N J Foot, T Chaplin, et al.
Lancet (London, England)|August 17, 1985
Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervixA A Epenetos, D Snook, G Hooker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 1999
Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapyJ Shamash, R T Oliver, J Ong, et al.
British Medical Journal (Clinical Research Ed.)|April 23, 1983
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancerJ H Waxman, J A Wass, W F Hendry, et al.
Oncology Reports|December 22, 1999
Concordance between tumour cell activation by epidermal growth factor and alteration of cell sensitivity to cisplatin and lymphokine-activated killer cell activityA M Nouri, S T Zubairi, M V Russell, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
The first clinical use of depot buserelin for advanced prostatic carcinomaJ H Waxman, J Sandow, A Man, et al.
Acta Oncologica (Stockholm, Sweden)|January 6, 2001
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?J Shamash, C A O'Doherty, R T Oliver, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1995
Secondary tumours following etoposide containing therapy for germ cell cancerC Boshoff, R H Begent, R T Oliver, et al.
BJU International|November 9, 2000
Computed tomography 21 days after chemotherapy, three-dimensional estimates of metastatic volume and the need for surgery in patients with germ cell cancerH S Bozcuk, R Ravi, B Turner, et al.
Pageof 16